Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6379-6386

  Crawford, Lisa J A ^a   Walker, Brian ^a   Ovaa, Huib ^c,e   Chauhan, Dharminder ^d   Anderson, Kenneth C ^d   Morris, Treen C M ^b   Irvine, Alexandra E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CHYMOTRYPSIN; PEPTIDE DERIVATIVE; PEPTIDYLGLUTAMYL PEPTIDE HYDROLYSING; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CATALYSIS; CELL LINE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SELECTIVITY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BORONIC ACIDS; CATALYSIS; CELL LINE, TUMOR; GLYOXAL; HELA CELLS; HUMANS; LEUCINE; LEUPEPTINS; OLIGOPEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SUBSTRATE SPECIFICITY;

EID: 33745728140     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0605     Document Type: Article

References (26)

1. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245-73.
2. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995;2:503-8.
3. Naujokat C, Hoffman S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002;82:965-80.
4. Groll M, Heinemeyer W, Jager S, et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci U S A 1999;96:10976-83.
5. Strehl B, Seifert U, Kruger E, Heink S, Kuckelcorn U, Kloetzel PM. Interferon-γ, the functional plasticity of the ubiquitin-proteasome system, and MHC class 1 antigen processing. Immunol Rev 2005;207:19-20.
6. Rock KL, Goldberg AL. Degradation of cell proteins and generation of MHC class 1-presented peptides. Annu Rev Immunol 1999;17:739-79.
7. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 2003; 4:251-6.
8. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999;50:57-74.
9. Kane HC, Bross PF, Farell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncology 2003;8:508-13.
10. Jaganneth S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83.
11. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin, and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-62.
12. Magill L, Lynas J, Morris TCM, Walker B, Irvine AE. Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukaemia and multiple myeloma. Haematalogica 2004;89:1428-33.
13. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63: 6174-7.
14. Lynas JF, Harriott P, Healy A, McKervey MA, Walker B. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl α-keto aldehydes (glyoxals). Bioorg Med Chem Lett 1998;8: 373-8.
15. Berkers CR, Verdoes M, Lichtman E, et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005;2: 357-62.
16. Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005;65:7896-900.
17. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliot PJ. Proteasome inhibition measurements: clinical applications. Clin Chem 2000;46:673-83.
18. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomb. Cancer Cell 2005;8:407-19.
19. Jager S, Groll M, Huber R, Wolf DH, Heinemeyer W. Proteasome β-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J Mol Biol 1999;291:997-1013.
20. Kisselev AF, Akopian TN, Castillo V, Goldberg AL. Proteasome active sites allosterically regulate each other suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 1999;4:395-402.
21. Kisselev AF, Callard A, Goldberg AL. Importance of the proteasome's different proteolytic sites and the efficacy of inhibitors varies with protein substrate. J Biol Chem 2006;281:8582-90.
22. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8:738-58.
23. Chauhan D, Pandley P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000;275:27845-50.
24. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-36.
25. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and trileucine. J Biochem 1996;119:572-6.
26. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Proteasome inhibition as a therapeutic strategy for haematological malignancies. Expert Rev Anticancer Ther 2005;5:465-76.